Clay Siegall Discusses About Genetic Testing And Its Benefits To The Development Of Cancer Therapies
Cancer has led to the death and disability of millions of people across the globe. This has made it to be one of the world’s most feared diseases. The most common forms of the disease are prostate cancer in men and breast cancer in women. However, several other types of cancer continue to affect many people globally. Cases of colon cancer and skin cancer have continued to grow at a very fast rate. According to Clay Siegall, early diagnosis of cancer increases chances of treating it. Clay is the co-founder of Seattle Genetics.
The field of cancer research has greatly benefited from the advancement of technology. With current fast genetic testing, the cost of genetic sequencing has significantly reduced. This has enabled cancer research institutes to research further using new techniques of diagnosing and treating cancer. To this end, there has been a significant improvement in the efficiency of new cancer therapies.
The human DNA code is made up of over 20,000 genes. The arrangement of these genes is unique to every individual. One’s DNA code is a result of his or her ancestry. Although the process of extracting the code remained extremely difficult, scientific advancements have reversed this situation. The complexity of the code still amazes scientists. In addition, it is not well understood how it affects the development of certain diseases. The process of unraveling this complex system is already ongoing. Moreover, the code is used to diagnose cancer. The information obtained from the codes is used to create targeted cancer therapies.
Cancer comes in various forms. Notably, the way in which each type affects an individual varies from one person to another. One’s genetic composition, hormones, and other biological makeup influence this process. The difference caused by these factors can result into an individual responding well to a treatment while the other fails. With genetic sequencing, this problem is eliminated. More people are able to benefit significantly from their treatments.
About Clay Siegall
Clay Siegall is a genetic expert. He is the chief executive officer of a Seattle-based corporation, Seattle Genetics. In addition, Siegall serves as the company’s president. Clay uses his expertise in the field to help in advancing cancer therapies. He mainly focuses on creating targeted cancer therapies using genetic and DNA mapping.
The executive is the holder of a bachelor’s degree in zoology from the renowned George Washington University. Formerly, he worked for the National Cancer Institute and Bristol-Myers Squibb Pharmaceutical Research Institute.